Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:31:02 EDT Mon 21 Apr 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login ID:
Password:
Save
C:RVV
- Revive Therapeutics Ltd. -
https://www.revivethera.com
00:31:02 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
RVV
- C
↑ATS
656.5
0.03
·
0.035
99.0
0.03
0.035 0.005
Apr 17
Apr 10
15 min
RT 2¢
CSE - C
656.5
0.03
·
0.035
99.0
0.03
0.035 0.005
Apr 17
15 min
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
NOTE: Delayed ATS trade data is included - click System Status for more information
Hide ATS
·
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
Company
·
Participants
·
1yr Bulletins
·
Sedar
·
Historical
·
Shorts
·
Portfolio
Recent Trades - All 0 today
More trades...
Time ET
Ex
Price
Change
Volume
Buyer
Seller
Markers
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Price
Type
Headline
2025-04-10 13:52
C:RVV
0.02
News Release
200
Revive to study bucillamine as cancer treatment
2025-04-01 16:35
C:RVV
0.015
News Release
200
Revive agrees to buy Diagnamed's molecular hydrogen IP
2025-03-19 17:28
C:RVV
0.01
News Release
200
Revive shareholders approve all matters at AGSM
2025-03-03 19:00
C:RVV
0.01
News Release
200
Revive to buy molecular hydrogen rights from Diagnamed
2025-02-28 18:44
C:RVV
0.01
SEDAR Interim Financial Statements
812
SEDAR Interim Financial Statements
2025-02-28 18:44
C:RVV
0.01
SEDAR Interim MD & A
813
SEDAR Interim MD & A
2025-02-03 21:30
C:RVV
0.01
News Release
200
Revive to complete Bucillamine study in February
2025-01-08 16:41
C:RVV
0.005
News Release
200
Revive Therapeutics talks bucillamine research study
2024-11-29 21:02
C:RVV
0.01
SEDAR Interim MD & A
813
SEDAR Interim MD & A
2024-11-29 20:36
C:RVV
0.01
SEDAR Interim Financial Statements
812
SEDAR Interim Financial Statements
2024-11-12 15:31
C:RVV
0.01
News Release
200
Revive talks BMC article on psilocybin research study
2024-10-31 15:17
C:RVV
0.01
News Release
200
Revive expects bucillamine study results by year-end
2024-10-28 15:53
C:RVV
0.01
SEDAR MD & A
815
SEDAR MD & A
2024-10-28 15:47
C:RVV
0.01
SEDAR Audited Annual Financial Statements
804
SEDAR Audited Annual Financial Statements
2024-09-18 11:52
C:RVV
0.01
News Release
200
Revive Therapeutics to focus on bucillamine
2024-08-28 10:21
C:RVV
0.015
News Release
200
Revive hopes to complete bucillamine study in October
2024-07-02 15:59
C:RVV
0.01
News Release
200
Revive begins bucillamine study on nerve agent exposure
2024-06-12 12:14
C:RVV
0.02
News Release
200
Revive receives FDA feedback on Bucillamine study
2024-06-10 11:22
C:RVV
0.02
News Release
200
Revive receives FDA feedback for diagnostic device
2024-05-31 01:25
C:RVV
0.025
SEDAR Interim MD & A
813
SEDAR Interim MD & A